Stocks and Investing Stocks and Investing
Wed, September 6, 2023

Asthika Goonewardene Reiterated (ACET) at Strong Buy and Held Target at $27 on, Sep 6th, 2023


Published on 2024-10-28 06:16:27 - WOPRAI, Asthika Goonewardene
  Print publication without navigation


Asthika Goonewardene of Truist Securities, Reiterated "Adicet Bio, Inc." (ACET) at Strong Buy and Held Target at $27 on, Sep 6th, 2023.

Asthika has made no other calls on ACET in the last 4 months.



There are 6 other peers that have a rating on ACET. Out of the 6 peers that are also analyzing ACET, 3 agree with Asthika's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Schmidt of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $20 on, Tuesday, June 27th, 2023
  • Reni Benjamin of "JMP Securities" Downgraded from Buy to Hold on, Tuesday, June 27th, 2023
  • Brian Cheng of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $6 on, Thursday, June 1st, 2023


These are the ratings of the 3 analyists that currently disagree with Asthika


  • Edward White of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $26 on, Friday, August 11th, 2023
  • Justin Zelin of "BTIG" Maintained at Strong Buy with Decreased Target to $10 on, Thursday, August 10th, 2023
  • Robert Driscoll of "Wedbush" Reiterated at Buy and Held Target at $17 on, Thursday, August 10th, 2023
Contributing Sources